Click on image to view larger version.

Figure 1 Comparison of rates of angiographic restenosis and target lesion revascularization (TLR) for diabetic patients enrolled in the Sirolimus-coated BX Velocity Balloon-Expandable Stent in the treatment of Patients with De Novo Coronary Artery Lesions (SIRIUS) (1), Polymer-Based Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease (TAXUS-IV) (2), and Intracoronary Stenting and Angiographic Results (ISAR-STEREO) (12,13) trials (95% confidence intervals [CI] are illustrated).